Table 1. Clinicopathologic features on... | American Society of Hematology

Table 1.

Clinicopathologic features on presentation and at relapse/refractory disease of 7 patients with NK/T-cell lymphoma treated with pembrolizumab

Case			On initial presentation			At relapse/refractory disease before pembrolizumab
Case	Sex	Age, y	Primary sites	Marrow	Stage	Sites	ECOG score	Marrow	Stage	HPS
1	M	68	Skin of lower limbs, nasal cavities	Negative	IV	Calf skin	1	Negative	I_E	Nil
2	M	49	Nasal cavities, lymph nodes, liver, spleen, bone	Negative	IV	Liver, spleen	1	Positive	IV	Yes
3	M	38	Nasopharynx	Negative	I_E	Nasopharynx, hard palate	2	Positive	IV	Yes
4	M	50	Liver	Positive	IV	Liver	3	Positive	IV	Yes
5	M	31	Nasal cavity, nasopharynx, masseter muscle, bone	Negative	IV	Nasal cavity, liver	2	Negative	IV	Yes
6	M	35	Nasal cavity	Negative	I_E	Lung, esophagus	2	Negative	IV	Nil
7	M	51	Liver, spleen	Positive	IV	Liver	1	Positive	IV	Yes

Case			On initial presentation			At relapse/refractory disease before pembrolizumab
Case	Sex	Age, y	Primary sites	Marrow	Stage	Sites	ECOG score	Marrow	Stage	HPS
1	M	68	Skin of lower limbs, nasal cavities	Negative	IV	Calf skin	1	Negative	I_E	Nil
2	M	49	Nasal cavities, lymph nodes, liver, spleen, bone	Negative	IV	Liver, spleen	1	Positive	IV	Yes
3	M	38	Nasopharynx	Negative	I_E	Nasopharynx, hard palate	2	Positive	IV	Yes
4	M	50	Liver	Positive	IV	Liver	3	Positive	IV	Yes
5	M	31	Nasal cavity, nasopharynx, masseter muscle, bone	Negative	IV	Nasal cavity, liver	2	Negative	IV	Yes
6	M	35	Nasal cavity	Negative	I_E	Lung, esophagus	2	Negative	IV	Nil
7	M	51	Liver, spleen	Positive	IV	Liver	1	Positive	IV	Yes

ECOG, Eastern Cooperative Oncology Group; HPS, hemophagocytic syndrome.